XVARY Composite Score
/ 100
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Artiva builds frozen immune-cell treatments for autoimmune disease and cancer.
How it gets paid
Last year Artiva Biotherapeutics made $0 in revenue.
Why growth slowed
Revenue fell 100.0% last year. Annual revenue was $0, so the quarter still looks like a research bill, not a business.
What just happened
Artiva posted $251K in revenue and -$2.59 EPS in the latest quarter.
At a Glance
N/a balance sheet
-$5.81 fy2024 eps est
$0M fy2024 rev est
~$153M market cap
Small cap
What They Do
Artiva builds frozen immune-cell treatments for autoimmune disease and cancer.
You do not order a custom cell therapy here. AlloNK is allogeneic (donor-derived), so one batch is made ahead and shipped frozen. That is cleaner than patient-by-patient manufacturing, but $0 annual revenue versus $8M of debt says the moat is still theoretical.
How They Make Money
$0
annual revenue · revenue declined -100.0% last year
The Products That Matter
Investigational cell therapy
allonk
one lead asset · $153M equity story
This asset carries almost the whole valuation. With $0 revenue today, a setback here would hit the thesis directly rather than denting one division.
binary catalyst
Development path
trial design
1H26 FDA interaction
Here is the quiet part loud: in a company this early, protocol design is strategy. A cleaner path into rheumatoid arthritis matters more than any quarterly operating metric.
the number that mattered
Capital structure
cash runway
$8M debt · $0 revenue
Debt looks manageable at $8M. That does not make funding risk disappear. In early biotech, equity financing often shows up before clinical proof shows up.
watch dilution
Key Numbers
$0
annual sales
No sales means every trial update matters more than a normal quarter.
$251K
quarterly sales
That is tiny next to the $153M market cap.
$8M
debt
Debt is small in dollars, but huge next to $0 sales.
89
headcount
A 89-person lab has to do what a much bigger company would usually do.
Financial Health
n/a
Strength
- balance sheet grade n/a
- long-term debt $8M (5% of capital)
n/a — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Artiva posted $251K in revenue and -$2.59 EPS in the latest quarter.
Annual revenue was $0, so the quarter still looks like a research bill, not a business. Gross margin was not disclosed.
$251K
revenue
-$2.59
eps
n/a
n/a
the number that mattered
The $251K quarter matters because it is tiny versus the $153M market cap.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The risk picture is company-specific and blunt: AlloNK execution in rheumatoid arthritis drives almost everything, because there is no revenue base to absorb delays and no broad product mix to hide behind.
High
No commercial sales
Annual revenue was $0, and the latest quarter was $251K. That leaves the company leaning on financing, not customers.
threatens the $8M debt load
High
Single-program risk
The company is tied to one lead program, AlloNK, across 3 ongoing trials. One weak dataset can hit the whole story.
could wipe out 100% of pipeline value
Med
Dilution risk
A $153M market cap leaves little room for mistakes when revenue is still near zero. Any capital raise can land directly on holders.
could cut your ownership by 20%
If revenue stays near $251K a quarter, financing matters more than trial slides.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Regulatory
The first-half 2026 FDA interaction is the key event
Management plans to discuss trial design for refractory rheumatoid arthritis. For a company this early, trial design is not paperwork. It is the roadmap.
Funding
Cash commentary matters as much as the science
You have $0 revenue and only $8M of long-term debt. That sounds clean until you remember that equity raises usually arrive before proof does.
Sentiment
The target spread is wide for a stock at $4.68
Published targets run from $10.00 to $19.00. That is not analyst unity. It is early-stage valuation uncertainty with decimal points.
Kill criteria
What would change our mind
If the March 30 update points to a slower FDA path or makes near-term financing look more likely before a cleaner clinical setup, the upside case weakens fast. That is the line to watch.
Analyst Rankings
consensus target
$19.00 +306%
in human-speak, published consensus says the stock is worth a lot more if the clinical path holds together.
recent named target
$10.00 +114%
Cantor Fitzgerald is still above the current price, but far below the broader $19.00 consensus. Same company. Very different underwriting.
coverage depth
thin early
The usual rank stack is thin here. That is common in small pre-revenue biotech, and it means you should trust the catalyst map more than any neat valuation table.
valuation spread
$9.00 wide
The gap between $10.00 and $19.00 is the number that mattered. Analysts agree on upside, not on how much of it belongs in the stock today.
Source: institutional data
Institutional Activity
institutional ownership data for ARTV is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$5
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive